Cancer Drug Responses Charlotte NC

new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

David Weldon Miller
(704) 302-8000
1025 Morehead Medical Dr
Charlotte, NC
Specialty
Internal Medicine, Hematology / Oncology

Data Provided by:
Jonathan C Salo
(704) 355-2884
1025 Morehead Medical Dr
Charlotte, NC
Specialty
Surgical Oncology

Data Provided by:
Robert W Fraser III, MD
(704) 333-7376
200 Queens Rd
Charlotte, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ Of Pa Sch Of Med, Philadelphia Pa 19104
Graduation Year: 1975
Hospital
Hospital: Rowan Reg Med Ctr, Salisbury, Nc; Carolinas Med Ctr, Charlotte, Nc
Group Practice: Southeast Radiation Oncology Group Matthews Rad Oncology; Southeast Radiation Oncology Group Pa; Southeast Radiation Oncology Group Rock Hill Rad Oncology; Sou

Data Provided by:
Mark Mogul
(704) 384-1900
1712 E 4th St
Charlotte, NC
Specialty
Hematology / Oncology, Pediatric Hematology-Oncology

Data Provided by:
Timothy Earl Cloninger, MD
(704) 333-7376
200 Queens Rd
Charlotte, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1966
Hospital
Hospital: Rowan Reg Med Ctr, Salisbury, Nc; Carolinas Med Ctr, Charlotte, Nc
Group Practice: Southeast Radiation Oncology Group Matthews Rad Oncology; Southeast Radiation Oncology Group Pa; Southeast Radiation Oncology Group Rock Hill Rad Oncology; Sou

Data Provided by:
Anthony Lawrence Asher, MD
(704) 376-1605
Carolina Neurosurgery and Spine Asociates 225 Baldwin Road
Charlotte, NC
Specialties
Neurological Surgery, Surgical Oncology
Gender
Male
Education
Medical School: Wayne State Univ Sch Of Med, Detroit Mi 48201
Graduation Year: 1982

Data Provided by:
Dr.Jayanthi Lea
(704) 355-2940
1025 Morehead Medical Dr # 600
Charlotte, NC
Gender
F
Speciality
Oncologist
General Information
Hospital: Carolina Medical Center
Accepting New Patients: Yes
RateMD Rating
1.0, out of 5 based on 1, reviews.

Data Provided by:
Mark Kirsch, MD
(704) 384-4189
PO Box 33549
Charlotte, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ Of The Witwatersrand, Med Sch, Johannesburg, So Africa
Graduation Year: 1969
Hospital
Hospital: Rowan Reg Med Ctr, Salisbury, Nc; Presbyterian Hospital, Charlotte, Nc
Group Practice: Southeast Radiation Oncology Group Matthews Rad Oncology; Southeast Radiation Oncology Group Pa; Southeast Radiation Oncology Group Rock Hill Rad Oncology;

Data Provided by:
Stephen Paul McClure
(704) 384-4814
200 Hawthorne Lane
Charlotte, NC
Specialty
Hematology

Data Provided by:
Stuart Heinrich Burri, MD
(704) 355-2273
200 Queens Rd Ste 400
Charlotte, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Emory Univ Sch Of Med, Atlanta Ga 30322
Graduation Year: 1995
Hospital
Hospital: Rowan Reg Med Ctr, Salisbury, Nc; Carolinas Med Ctr For Mental H, Charlotte, Nc
Group Practice: Southeast Radiation Oncology Group Matthews Rad Oncology; Southeast Radiation Oncology Group Pa; Southeast Radiation Oncology Group Rock Hill Rad

Data Provided by:
Data Provided by:

Cancer Drug Responses

Provided By:

A new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Avastin, which shrinks tumors by cutting off their blood supply, was approved this spring by the U.S. Food and Drug Administration for treatment of aggressive brain cancer. However, half of those with the cancer don't respond to the drug, which can cost up to $10,000 a month, according to a news release from the University of California, Los Angeles.

UCLA researchers examined 82 people who had surgery and radiation to treat glioblastoma, the most common and deadly form of adult brain cancer. Half of them were given infusions of Avastin every two weeks, and all had monthly MRI brain scans to monitor changes.

An analysis of the scans showed that there was greater water movement in the tumors of people who later had the best response to Avastin. By using MRI to measure the amount of water motion within the tumor, the researchers were able to predict with 70 percent accuracy which tumors would progress within six months and which would not.

Increased water movement in tumors is linked with higher levels of a growth factor called VEGF, which is secreted by a tumor to promote the growth of new blood vessels that provide the tumor with oxygen and nutrients. Avastin blocks VEGF, the researchers explained.

"When we realized that high levels of VEGF are linked to greater cell death and increased water movement, we were able to predict the patients' response to Avastin before they began treatment," lead author Dr. Whitney Pope, assistant professor of radiological sciences at UCLA's David Geffen School of Medicine, said in the news release.

"We were correct 70 percent of the time," Pope said. "Previously, identifying which patients would respond was like flipping a coin. This is a huge improvement."

The study appears in the July issue of Radiology.

"Knowing this information ahead of time will help doctors personalize therapy for each patient and decrease exposure to side effects," Pope said.

He and a co-author are consultants for Genentech, which makes Avastin, and are working with the company on several research studies.

More information

The U.S. National Cancer Institute has more about brain tumors.

SOURCE: University of California, Los Angeles, news release, July 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com